清肝化湿活血汤联合保肝降酶药物治疗酒精性肝病的效果分析

姚志山; 刘丁丁; 云翔

doi:10.3969/j.issn.1001-5256.2016.08.025

清肝化湿活血汤联合保肝降酶药物治疗酒精性肝病的效果分析

DOI: 10.3969/j.issn.1001-5256.2016.08.025

1. 唐山市丰润区第二人民医院内四科
2. 华北理工大学中医学院
3. 内蒙古北方重工业集团有限公司医院工业卫生科

基金项目:

河北省中医药管理局课题基金项目(2016240)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2372
- HTML全文浏览量: 61
- PDF下载量: 417
- 被引次数: 0
出版历程
- 收稿日期: 2016-03-08
- 出版日期: 2016-08-20

Clinical efficacy of Qinggan Huashi Huoxue decoction combined with liver-protecting and enzyme-lowering drugs in treatment of alcoholic liver disease

Fourth Department of Internal Medicine,The Second People's Hospital of Fengrun District,Tangshan

Research funding:

摘要

摘要:
目的观察中药清肝化湿活血汤联合保肝降酶药物治疗酒精性肝病（ALD）的安全性及临床疗效。方法收集2012年1月-2015年12月于唐山市丰润区第二人民医院收治的ALD患者175例,随机分为治疗组（n=87）和对照组（n=88）。对照组采用戒酒、营养支持、多烯磷脂酰胆碱、还原性谷胱甘肽、异甘草酸镁、熊去氧胆酸胶囊等治疗,治疗组在对照组治疗方案的基础上加用自拟中药清肝化湿活血汤。治疗3个疗程（12周）的过程中,观察患者的临床症状和体征,并定期复查肝功能（ALT、AST、GGT、白蛋白、TBil）、血脂[总胆固醇、甘油三酯、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）]、血常规、肝脏超声等检测结果,并记录治疗过程中的不良反应。计量资料组间比较采用独立样本t检验,2组间治疗过程中各时间节点差异的比较采用重复测量方差分析,计数资料组间比较采用χ2检验。结果治疗后2组患者的临床症状和体征均得到不同程度的改善,2组间治疗4、8、12周比较差异均有统计学意义（t值分别为14.390、10.487、13.547,P值均<0.05）;2组患者的肝功能指标在治疗4、8、12周时均有不同程度改善,2组在...
- 肝疾病,酒精性 /
- 清肝化湿活血汤 /
- 治疗
Abstract:
Objective To investigate the clinical efficacy and safety of Qinggan Huashi Huoxue decoction combined with liver- protecting and enzyme- lowering drugs in the treatment of alcoholic liver disease( ALD). Methods A total of 175 ALD patients who were admitted to The Second People's Hospital of Tangshan from January 2012 to December 2015 were enrolled and randomly divided into treatment group( 87patients) and control group( 88 patients). The patients in the control group were asked to quit smoking and were given nutritional support and medications including polyene phosphatidylcholine,reduced glutathione,magnesium isoglycyrrhizinate,and ursodeoxycholic acid capsules,and those in the treatment group were given the self- made traditional Chinese medicine Qinggan Huashi Huoxue decoction in addition to the therapeutic regimen for the control group. During the three courses of treatment( 12 weeks),the patients' clinical symptoms and signs were observed,liver function [alanine aminotransferase( ALT),aspartate aminotransferase( AST),gamma- glutamyl transpeptidase( GGT),albumin( Alb),and total bilirubin( TBil) ]and blood lipids [total cholesterol( TC),triglyceride( TG),high- density lipoprotein( HDL),and low- density lipoprotein( LDL) ] were performed regularly,the results of routine blood tests and abdominal ultrasound findings were recorded regularly,and adverse events which occurred during treatment were recorded. The independent samples t- test was used for comparison of continuous data between groups,an analysis of variance with repeated measures was used to compare the differences at each time point between the two groups,and the chi- square test was used for comparison of categorical data between groups. Results After treatment,all patients achieved varying degrees of improvements in clinical symptoms and signs,which showed significant differences between the two groups at weeks 4,8,and 12 of treatment( t = 14. 390,10. 487,and 13. 547,all P < 0. 05). The liver function parameters in the two groups showed varying degrees of improvements at weeks 4,8,and 12 of treatment,and ALT,AST,and GGT showed significant differences between the two groups at weeks 4,8,and 12 of treatment( F = 21. 050,8. 108,and 12. 038,all P < 0. 01). In the control group,HDL showed a significant change after treatment( t = 3. 101,P < 0. 05),and in the treatment group,HDL and LDL showed significant changes after treatment( t = 6. 818 and 2. 532,both P < 0. 05). After treatment,HDL showed a significant difference between the two groups( t = 2. 784,P < 0. 05). The overall response rate also showed a significant difference between the control group and the treatment group( 53. 4% vs 82. 8%,χ2= 28. 74,P < 0. 001). No patient experienced significant adverse events during treatment. Conclusion Qinggan Huashi Huoxue decoction combined with liver- protecting and enzyme- lowering drugs can improve the clinical outcome of ALD patients and holds promise for clinical application.
- liver disease /
- alcoholic /
- Qinggan Huashi Huoxue decoction

HTML全文

参考文献(16)

[1] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association,Chinese Medical Association.Guideline for prevention and treatment of alcoholic liver disease(revised version 2010)[J].J Clin Hepatol,2010,26(3):229-232.(in Chinese)中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.酒精性脂肪性肝病诊疗指南(2010年修订)[J].临床肝胆病杂志,2010,26(3):229-232.

[2]SONG SL.Clinical efficacy of tiopronin combined with Danshen injection in treatment of alcoholic liver disease[J].Chin Hepatol,2015,20(9):711-715.(in Chinese)宋秀丽.硫普罗宁联合丹参注射液治疗酒精性肝病临床疗效[J].肝脏,2015,20(9):711-715.

[3]ZHAN ZY,SUN MY.Traditional Chinese medicine treatment and research progress of alcoholioc liver disease[J].Sichuan J Tradit Chin Med,2014,32(10):182-186.(in Chinese)詹宗颖,孙明瑜.酒精性肝病的中医治疗及研究进展[J].四川中医,2014,32(10):182-186.

[4] State Administration of Traditional Chinese Medicine.Criteria of diagnosis and therapeutic effect of diseases and syndromes in traditional chinese medicine(2012 Edition)[M].Beijing:Chinese Midical Science and Technology Publishing House,2012:16-17.(in Chinese)国家中医药管理局.中医病症诊断疗效标准(2012年版)[M].北京:中国医药科技出版社,2012:16-17.

[5]ZHENG XY.Guideline for clinical research of Chinese midicine(New drugs)(Trial)[M].Beijing:Chinese Midical Science and Technology Publishing House,2002:147-151.(in Chinese)郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:147-151.

[6]ZHU HY,LI TY,CHEN J.Diagnosis and treatment progress of alcohol liver disease[J].Med Recapitulate,2014,20(14):2556-2559.(in Chinese)朱慧艳,李婷冶,陈洁.酒精性肝病的诊断和治疗进展[J].医学综述,2014,20(14):2556-2559.

[7]QI F,CHEN LY,SUN YL.Protective effect of Lingxu liver-protecting tablets on alcohol-induced liver injury[J].J Changchun Univ Tradit Chin Med,2015,31(2):232-234.(in Chinese)綦菲,陈丽艳,孙银玲.灵须护肝片对急性酒精性肝损伤的保护作用[J].长春中医药大学学报,2015,31(2):232-234.

[8]YANG Y,LU XL.Research of the pathogenesis of alcoholic liver disease[J].Chin J Gastroenterol Hepatol,2014,23(9):990-993.(in Chinese)杨燕,鲁晓岚.酒精性肝病发病机制研究的最新进展[J].胃肠病学和肝病学,2014,23(9):990-993.

[9]ZHANG YB,PENG YF,YE TS,et al.Clinical curative effect of Huoxue Huatan Hugan Formula on alcoholic fatty liver disease[J].Chin J Integr Tradit West Med Liver Dis,2015,25(3):154-155.(in Chinese)张亚兵,彭艳芳,叶太生,等.活血化瘀护肝汤治疗酒精性脂肪肝50例[J].中西医结合肝病杂志,2015,25(3):154-155.

[10]YAO ZS,ZHANG HL,LIU DD,et al.Association of TCM syndrome types of alcoholic liver disease with liver function and blood lipid[J].Chin J Integr Tradit West Med Liver Dis,2016,26(1):48-50.(in Chinese)姚志山,张会玲,刘丁丁,等.酒精性肝病中医证型与肝功能、血脂的相关性分析[J].中西医结合肝病杂志,2016,26(1):48-50.

[11]WANG SP,CHEN MW,WANG YT.Research progress on chemical constituents and pharmacologocal activtities of Flor Puerariae[J].Pharmocol Clin Chin Mater Med,2012,28(2):193-196.(in Chinese)王胜鹏,陈美婉,王一涛.葛花化学成分和药理活性研究进展[J].中药药理与临床,2012,28(2):193-196.

[12]LI F,LI JB,ZHANG DM.Research advances in the pharmacology of Bupleurum chinense[J].Lishizhen Med Mater Med Res,2004,15(2):120-121.(in Chinese)李芳,李建北,张东明.柴胡的药理研究进展[J].时珍国医国药,2004,15(2):120-121.

[13]LI Q.Pharmacological studies on Rheum officinale and its clinical application[J].Mod J Integr Tradit Chin West Med,2009,18(22):2740-2741.(in Chinese)李强.大黄药理与临床应用[J].现代中西医结合杂志,2009,18(22):2740-2741.

[14]LAN FY.Pharmacological studies on Radix Curcumae and its clinical application[J].J Changchun Univ Tradit Chin Med,2009,25(1):27-28.(in Chinese)兰凤英.郁金的药理作用及临床应用[J].长春中医药大学学报,2009,25(1):27-28.

[15]YAO ZS,PEI SH,YIN DW.Characteristics of abnormal blood lipid metabolism in patients with alcoholic or nonalcoholic fatty liver disease[J].Chin Hepatol,2015,20(1):47-50.(in Chinese)姚志山,裴士会,尹东武.酒精性与非酒精性脂肪性肝病血脂代谢异常特点[J].肝脏,2015,20(1):47-50.

[16]QU BG,WANG H,SU JL,et al.Relationship between alcoholic fatty liver disease and carotid intima-media thickness and influencing factors for carotid intima-media thickness[J].J Clin Hepatol,2015,31(2):256-260.(in Chinese)曲宝戈,王慧,苏吉亮,等.酒精性脂肪性肝病患者颈动脉内膜中层厚度增加的影响因素分析[J].临床肝胆病杂志,2015,31(2):256-260.

施引文献

资源附件(0)

访问统计